CRSP - IBB: Lows After Highs Highlight Failing Growth Narratives And Overvaluation In Biotech Sector

• Biotech stocks had enjoyed strong hype and trajectories in the recent past, especially during the pandemic years. This is beginning to unravel.
• ETFs covering this sector have a massive preponderance of U.S. stocks, historically the most overvalued market in the world.
• As growth stories crumble, so do the stock prices. Overall, the sector isn't very attractive to invest into at the present.
• After the floor on valuations, however, there may be a case for investment. Predicting a timeline, however, cannot be done in good faith.

For further details see: